Keywords: Pfizer, Tofacitinib, Rheumatoid arthritis, Phase III
Pfizer’s tofacitinib meets Ph III endpoints in patients with active RA
Article | 07 March 2011
Global drugs behemoth Pfizer (NYSE:PFE) says that tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor being studied ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
